Children and young adults who receive CAR T-cell therapy for the most common childhood cancer, acute lymphoblastic leukemia, suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired ...
Apr 1, 2021
0
6
Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.
Mar 31, 2021
0
3
In cancer immunotherapy, cells in the patient's own immune system are activated to attack cancer cells. CAR T cell therapy has been one of the most significant recent advances in immunotherapies targeted at cancer.
Mar 18, 2021
0
42
Researchers led by Professor Carolyn King of the University of Basel have developed a method to study the specialization of T cells in the context of infections. In the journal eLife, they report the different directions ...
Mar 10, 2021
0
12
Insight into cancer cells' own first aid could help the development of a new type of treatment. Johanna Olweus and her team at the UiO (University of Oslo) and the OUS (Oslo University Hospital) are important contributors ...
Jan 27, 2021
0
5
Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are ...
Jan 12, 2021
0
98
Activating an immune signaling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers ...
Dec 31, 2020
0
21
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients ...
Dec 7, 2020
0
2
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy ...
Dec 3, 2020
0
591
